8/4/2011

Tests on mice and monkeys showed that an experimental vaccine, made of viruslike particles, stimulated neutralizing antibodies to fight off multiple variants of hepatitis C virus, French scientists reported in Science Translational Medicine. Epixis CEO Charlotte Dalba said she expects the company to begin testing the vaccine in humans next year, provided it has enough funding. The French startup holds commercial rights to the vaccine.

Full Story:
Reuters

Related Summaries